RSV Antibody Reduces Infant Hospitalization by 73%

The U.S. Centers for Disease Control and Prevention (CDC) confirmed last month that respiratory syncytial virus (RSV) is the most common cause of hospitalization among U.S. infants.

Since last year, when Beyfortus™ became the first U.S. FDA-approved single-dose, extended half-life monoclonal antibody (mAb) offering passive immunization to prevent lower respiratory tract infections caused by RSV, numerous researchers have focused on determining its real-world effectiveness.

The CDC has clarified that mAbs are not vaccines but offer disease protection.

According to a study's results published by The Lance in October 2024 (Volume 8, Issue 10p721-729), Beyfortus's estimated effectiveness against RSV-associated hospitalizations for bronchiolitis was 73% (61–84), corresponding to one hospitalization averted for every 39 (26–54) doses administered.

And in sensitivity analyses, nirsevimab remained effective against RSV-associated hospitalizations for bronchiolitis after emergency department attendance.

As of October 4, 2024, there is ample supply of Beyforus in the U.S., well ahead of the 2024-2025 RSV season's peak, expected in December or January.